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Objectives
Lymphoproliferative disorders are often observed in HIV-positive patients. Combination
antiretroviral treatment (cART) during antineoplastic chemotherapy is beneficial, but little is
known about the clinical outcome according to different antiretroviral combinations. The aim of
the study was to address this gap in current knowledge.
Methods
A retrospective study was conducted in five large Italian centres for the period from 1998 to 2015;
HIV-positive patients diagnosed with lymphoma were included and demographic, clinical and
therapeutic variables were recorded and associated with clinical outcomes. Bivariate and
multivariate analyses were performed, including Cox proportional hazard models for survival.
Results
A total of 399 patients were included in the study. The most common types of lymphoma were
diffuse large B-cell lymphoma (DLCLB; n = 164), Hodgkin lymphoma (HL; n = 99) and Burkitt
lymphoma (BL; n = 57), followed by plasmablastic lymphoma (PBL; n = 38), T-cell lymphoma
(TCL; n = 17), indolent lymphoma (n = 10) and other less common types (n = 14). cART was given
to 327 (out of 387 evaluable) patients: in 216 subjects it was protease inhibitor (PI)-based, in 73 it
was nonnucleoside reverse transcriptase inhibitor (NNRTI)-based and in 18 it was integrase strand
transfer inhibitor (INSTI)-based (the remaining 20 individuals received other regimens). The 5-year
overall survival was 57.5% (52.8% for DLCLB, 67.8% for HL, 42.3% for BL, 60.6% for PBL and
64.7% for TCL). PI-based ART compared with other compounds was associated with worse survival
in non-Hodgkin lymphoma (NHL) and HL patients combined (P ≤ 0.001) and in NHL patients alone
(P < 0.001); grade 3–4 haematological toxicities were more commonly observed in PI-treated
individuals. Lymphoma diagnosis in recent years, better immunovirological status, lower
lymphoma stage and better prognostic indexes were associated with better survival.
Conclusions
PI-based cART while on chemotherapy was associated with worse overall survival and more
frequent haematological complications in HIV-positive patients with lymphoma.
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Introduction
HIV-related lymphomas (HRLs) include a spectrum of dif-
ferent pathological entities, each representing a major
complication in the natural history of HIV infection.
Their clinical outcome is associated with variables related
both to the severity of the neoplastic disease and to the
patients’ immunovirological status [1,2]. Since the intro-
duction of combination antiretroviral therapy (cART), a
remarkable change in HRL incidence and prognosis has
been observed. On the one hand, epidemiological data
indicate a significant decrease in the absolute incidence
of the most aggressive non-Hodgkin lymphoma (NHL)
histotypes, and a trend for an increase in the incidence of
histotypes with better prognosis such as Hodgkin lym-
phoma (HL) [3]. On the other hand, a positive direct effect
of cART has been suggested, with stronger evidence for
an improvement of patients’ immunovirological status at
lymphoma diagnosis, and more controversial data on
cART modulation of chemotherapy-induced immune sup-
pression [4,5]. Combining cART with chemotherapy has
been shown to reduce the incidence of chemotherapy-
and AIDS-related infectious complications in HRL
patients [6]. Moreover, the rate of complete response (CR)
to first-line chemotherapy has been shown to be
increased by cART in several studies [6–8]; this resulted
in an improvement in overall survival (OS) [9,10].
However, there exists a significant potential for pharma-
cokinetic (PK) interactions between chemotherapy and
antitroviral agents, which stems from their shared metabolic
pathways involving hepatic cytochromes. Overall, nonnu-
cleoside reverse transcriptase inhibitors (NNRTIs) as a group
induce cytochromes essential for metabolism of chemother-
apy agents, while protease inhibitors (PIs) tend to inhibit
them. Thus, some argue that NNRTIs share the potential to
reduce the concentrations, efficacy and adverse effects of
chemotherapy agents, while PIs would exert the opposite
effect. Nucleoside reverse transcriptase inhibitors (NRTIs)
and integrase strand transfer inhibitors (INSTIs) seem to
have very few significant drug-to-drug interactions (DDIs).
In vivo PK studies demonstrated a significant effect of PIs
on the area under the curve (AUC) for cyclophosphamide in
the Cyclophosphamide, Hydroxydaunorubicin (also called
doxorubicin or adramycin), Oncovin (vincristine), Predni-
sone or Orednisolone (CHOP) regimen [11], and for
vinblastine in the Adriamycin (hydroxydaunorubicin/
doxorubicin), Bleomycin, Vinblastine, Dacarbazine (ABVD)
regimen [12]. For doxorubicin, there is no apparent effect
on plasma concentrations, with some authors suggesting an
effect on intracellular concentrations [11,13]. In parallel
with a beneficial influence of cART on survival and
chemotherapy-related infectious complications, some
clinical studies on HRLs have shown an increase in other
chemotherapy-related complications, including cytopaenias
and neurotoxicity, in patients receiving cART [14,15]. Only
a few groups have compared outcomes for patients with
HRLs on different cART regimens during chemotherapy
[16]. While there is evidence for some influence of the cART
subtype on various clinical outcomes, the magnitude of the
effect has been found to vary in different studies. A
prospective study in NHL patients on the cyclophospha-
mide, doxorubicin, etoposide (CDE) infusional chemother-
apy regimen reported a significant association between
PI-based cART and a higher incidence of grade 3–4
infections, grade 4 neutropaenia and lower chemotherapy
dose-density [17]. A significantly higher incidence of severe
cytopaenias was observed in patients on PI-based cART
receiving ABVD chemotherapy for HL [18]. A Korea-based
study showed no evidence of an association between PI use
and the incidence of febrile neutropaenia in HRL patients
[19]. A higher CR rate in HRL patients on PI-based cART
was suggested in a retrospective series of 34 patients, but
there was an unequal distribution of lymphoma-related
prognostic variables among the study groups [20].
The potential for PK interactions seems limited for cART
regimens based on the unboosted integrase inhibitor (INI)
raltegravir, and observational data show their feasibility
and efficacy for HRL patients on chemotherapy [21].
The aim of the study was to analyse the choice of
antiretroviral regimens as a prognostic factor and predic-
tor of chemotherapy-associated toxicities in HIV-positive
patients diagnosed with lymphomas.
Methods
We retrospectively identified all consecutive patients
diagnosed with HIV-related lymphoma at five Italian
institutions between 1998 and 2015. Patients were
included if a western blot-confirmed diagnosis of HIV
infection and a biopsy-confirmed lymphoma diagnosis
were both ascertained. The protocol was approved by
each institution’s review board and all efforts were made
to obtain patients’ written consent.
Clinical records were retrospectively reviewed for the
following clinical characteristics: age, gender, ethnicity,
HIV risk group, hepatitis C virus (HCV) and hepatitis B
virus (HBV) infection status, comorbidity burden, dura-
tion of HIV infection prior to lymphoma diagnosis and
AIDS-defining events (remote or concurrent with lym-
phoma diagnosis). We divided the study time into three
different periods: 1998–2003, 2004–2008 and 2009–2015.
Viro-immunological parameters were CD4 T-cell count
and HIV RNA level at different time-points for the CD4
count, the historic CD4 count nadir ‘baseline’ at lymphoma
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diagnosis, the CD4 count 3 months into chemotherapy and
that at chemotherapy completion were used.
Patients who received cART were categorized according
to whether they were cART experienced or na€ıve prior to
lymphoma diagnosis and according to their baseline
cART regimen at the start of chemotherapy.
The characteristics of the lymphoma were recorded as
lymphoma histotype, lymphoma staging according to the
Ann Arbor system, the number of extranodal sites, the
prognostic score (International prognostic index (IPI) and
International prognostic score (IPS), respectively, for NHL
and HL) and the chemotherapy regimen.
Adverse events were expressed as the presence of
significant reductions in dose-density as a result of
chemotherapy toxicity, infectious complications, occur-
rence of haematological toxicity grade 3 or 4 according to
the Common Terminology Criteria for Adverse Events
(CTCAE) classification, the occurrence of neuropathy, the
occurrence of relapse, overall survival, and cause of death.
Prognostic scores were categorized as follows: low
(IPI 0–1; IPS 0–1), intermediate (IPI 2–3; IPS 2–4) and
high risk (IPI 4–5; IPS 5–7). These categories were anal-
ysed according to descriptive statistics.
Comorbidity burden was expressed as an adjusted
Charlson comorbidity index, not including AIDS in the
calculated score. A significant dose-density reduction was
defined as either a delay in chemotherapy completion of
more than a third of the scheduled duration, or a > 30%
dose reduction for at least one chemotherapy agent, in both
cases in response to chemotherapy-related toxicity.
Infectious complications were categorized as typical
chemotherapy-associated infections (e.g. febrile neutropae-
nia, sepsis, pneumonia or urinary tract infection) or
HIV-specific opportunistic infections (e.g. Candida
oesophagitis, Pneumocystis jirovecii pneumonia or tubercu-
losis). Neuropathy was defined either by Electromyography
(EMG) or by obvious clinical features as evident in clinical
records.
For univariate analysis, v2, Kruskall–Wallis tests and
Kaplan–Meier models were used. Factors with P < 0.10 in
univariate analysis were included in a multivariate model
for independence of association. Stepwise selection mod-
els were applied to binary logistic regression analysis (di-
chotomic variables of interest) and to Cox proportional
hazard models (survival). Binary logistic regression for
identifying variables associated with chemotherapy-
related complications was adjusted for baseline CD4
count and cART use (none vs. PI-based vs. other
antiretrovirals) and for variables with P < 0.10 in uni-
variate analysis. All statistical calculations were per-
formed with the SPSS program version 23.0 (IBM SPSS
Statistics. Armonk, NY, United States).
Results
Baseline characteristics
Three hundred and ninety-nine patients were included in
the study. They were mostly male (323; 81.1%) and their
median age was 43.6 years [interquartile range (IQR)
38.2–50.5 years]. The median baseline CD4 T-cell count
and CD4/CD8 ratio were 218 (IQR 102–348) cells/lL and
0.30 (0.15–0.51), respectively. One hundred and twenty
subjects were cART-na€ıve at lymphoma diagnosis [with a
median HIV RNA of 4.91 log10 HIV-1 RNA copies/mL
(IQR 4.38–5.48) at lymphoma diagnosis], while 264 were
on cART, with 114 (43%) showing plasma HIV RNA < 50
copies/mL. AIDS-related comorbidities were observed in
125 patients (32.6%); 267 individuals (66.9%) had a high
general comorbidity burden (Charlson index > 1).
Patients were diagnosed with diffuse large B-cell
lymphoma (DLCLB; 164 patients), HL (99 patients), Burkitt
lymphoma (BL; 57 patients), plasmablastic lymphoma
(PBL; 38 patients), indolent lymphoma (10 patients), T-cell
lymphoma (17 patients) and other less common types (four
patients). Among the three most prevalent lymphoma
histotypes (DLBCL, HL and BL), there were no statistically
significant differences in terms of gender, ethnicity, HIV
risk group and year of lymphoma diagnosis (Table 1). At
the time of lymphoma diagnosis, patients with HL had a
higher CD4 percentage (22% vs. 13.4% for DLCLB and
14.8% for BL; P < 0.001) and lower HIV RNA levels (44.4%
suppressed vs. 30% for DLCLB and 23% for BL; P < 0.001)
compared with other histologies. Overall, most patients had
advanced stage lymphoma (stage 3–4, 283; 70.9%) and
intermediate/high prognostic score results (IPI/IPS > 2,
249; 79%). HL patients had a higher incidence of bone
marrow involvement (36.0% vs. 20.4% for DLCLB and
27.5% for BL; P = 0.034) and a lower risk of extranodal
involvement other than bone marrow (21.7% vs. 49.7% for
DLCLB and 61.1% for BL; P < 0.001).
Antiretroviral and antineoplastic treatments
Among 387 evaluable patients, 327 (84.5%) received ART
after lymphoma diagnosis: PI-based in 216 (55.8%),
NNRTI-based in 73 (18.8%), INSTI-based in 18 (4.6%),
NRTI-only-based in 12 patients (2.1%) and other combi-
nations in eight individuals (2.1%).
Details of chemotherapy regimens were available in 367
patients; 11 subjects (3.1%) did not start any antineoplastic
agent, while 356 patients (89.2%) were treated with
chemotherapy or other treatment for lymphoma. Among
patients with DLCLB, 109 of 152 evaluable patients
received CHOP or CHOP-like regimens (71.7%), 12 CDE
(7.9%), 11 M-BACOD (methotrexate with leucovorin,
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bleomycin, doxorubicin, cyclophosphamide, vincristine,
and dexamethasone) (7.2%), eight ProMACE-CytaBOM
(cyclophosphamide, doxorubicin, etoposide cytozar, bleo-
mycin, vincristine, methotrexate and prednisone) (5.2%),
and 10 other chemotherapy regimens. Twenty-four (out of
28 evaluable patients) with PBL received CHOP or CHOP-
like regimens (85.7%). Among patients with HL, 44 of 60
evaluable patients received ABVD (73.3%). Thirty of 54
evaluable patients (55.5%) with BL received intensive regi-
mens (containing high-dose methotrexate), and 24 (44.4%)
received standard dose chemotherapy (mainly CHOP).
Patients with T-cell (T) NHL and low-grade NHL received
mainly CHOP. Most DLCLB and BL patients (62% and 70%,
respectively) received rituximab treatment and its use
increased in more recent years (59% in 2009–2015 vs. 60%
in 2004–2008 vs. 33.3% in 1998–2003; P < 0.001).
Survival
Five-year OS was 57.5%; median follow-up was
95 months (average 153 months; IQR 14–275 months). It
varied according to histotype as follows: 52.8% (DLCLB),
67.8% (HL), 42.3% (BL), 60.6% (PBL) and 64.7% (T-cell
lymphoma; Fig. 1).
For outcome analysis, patients were grouped into three
categories: all subjects, patients with NHL (DLCBL, PBL
and BL, including rituximab use as a covariate) and those
with HL. Results of univariate (log-rank test) and multi-
variate analysis (Cox proportional hazard model) are
shown in Table 2. Survival according to cART choice is
depicted in Figure 1. PI coadministration was signifi-
cantly associated with a higher mortality compared with
other antiretrovirals (NNRTI, INSTI and NRTI-only regi-
mens) in all patients (45.6% vs. 20.2%, respectively;
P ≤ 0.001) and in those with NHL (51.8% vs. 23.5%,
respectively; P < 0.001) but not in those with HL (34.6%
vs. 19%, respectively; P = 0.211).
In all patients who received a diagnosis in recent years,
higher baseline CD4 count and the use of cART avoiding
PIs were independently associated with better survival
(Table 2). In patients with NHL, younger age, higher base-
line CD4 count and the use of cART avoiding PIs were
independently associated with better survival. In patients
with HL (as a consequence of the smaller sample size),
Table 1 Patients’ characteristics at baseline according to the five main lymphoma histogroups
Variable DLCLB HL BL PBL TCL
n 164 99 57 38 17
Age (years) 43 (38–49) 45 (40–53) 42 (35–50) 43 (38–52) 44 (37–55)
Gender (male) 127 (77) 78 (78.8) 50 (87.7) 35 (92.1) 13 (76.5)
Geographical origin
Europe 141 (92.2) 91 (96.8) 55 (98.2) 35 (92.1) 15 (93.8)
Africa 8 (5.2) 0 (0) 1 (1.8) 2 (5.3) 0 (0)
Asia 2 (1.4) 1 (1.1) 0 (0) 1 (2.6) 1 (6.3)
Other 2 (1.3) 2 (2.1) 0 (0) 0 (0) 0 (0)
Risk factor for HIV acquisition
IDU 56 (41.8) 32 (39.0) 11 (19.6) 7 (21.9) 7 (46.7)
MSM 23 (15.0) 19 (23.2) 13 (23.2) 13 (40.6) 4 (26.7)
Heterosexual 55 (35.9) 26 (31.7) 23 (41.1) 12 (27.5) 4 (26.7)
Calendar year
1998–2003 51 (31.3) 28 (28.3) 11 (19.3) 6 (15.8) 10 (58.8)
2004–2008 57 (35.0) 28 (28.3) 26 (45.6) 9 (23.7) 5 (29.4)
2009–2015 55 (33.7) 43 (43.4) 20 (35.1) 23 (60.5) 2 (11.8)
CD4 T lymphocytes (cells/lL) 202 (91–363) 250 (135–348) 208 (115–341) 234 (87–440) 127 (47–306)
Baseline CD4/CD8 ratio 0.26 (0.13–0.40) 0.42 (0.26–0.70) 0.30 (0.12–0.44) 0.30 (0.10–0.50) 0.21 (0.05–0.37)
HIV RNA (log10 copies/mL) 4.16 (1.69–5.18) 1.69 (< 1.69–4.08) 4.12 (1.69–5.15) 2.01 (1.69–4.76) 3.66 (2.35–4.91)
Plasma HIV RNA < 50 copies/mL 39 (27.5) 46 (53.5) 13 (25.5) 15 (45.5) 2 (12.5)
Time between HIV and lymphoma diagnoses (years) 0.7 (0.1–15.8) 6.9 (2.5–18) 2 (1–9.4) 1.1 (0–4.5) 10.6 (0.6–4.1)
Carlson comorbidity index > 1 114 (69.5) 61 (61.6) 36 (63.2) 25 (65.8) 11 (64.7)
Advanced lymphoma stage (III/IV) 118 (77.1) 64 (74.4) 48 (84.2) 32 (94.1) 9 (64.3)
Bone marrow involvement 29 (20.4) 32 (36) 4 (27.5) 9 (24.3) 3 (21.4)
Extranodal involvement (≥ 1 site apart from bone marrow) 77 (49.7) 18 (21.7) 33 (61.1) 20 (54.1) 7 (46.7)
Prognostic score
Low risk 32 (29.1) 13 (24.1) 11 (20) 5 (14.7) 2 (18.2)
Intermediate risk 72 (43.9) 26 (48.1) 25 (45.5) 18 (52.9) 7 (63.3)
High risk 41 (28.3) 15 (27.8) 19 (34.5) 11 (32.4) 2 (18.2)
Values are n (%) or median (interquartile range).
Prognostic scores: low (IPI 0–1; IPS 0–1), intermediate (IPI 2–3; IPS 2–4) and high risk (IPI 4–5; IPS 5–7).
BL, Burkitt lymphoma; DLCBL, diffuse large B-cell lymphoma; PBL, plasmablastic lymphoma; TCL, T-cell lymphoma; HL, Hodgkin lymphoma; IDU, inject-
ing drug user; MSM, men who have sex with men.
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correlated variables were selected according to the stron-
gest association in univariate analysis. In patients with
HL, a diagnosis in recent years and bone marrow nonin-
volvement were associated with better survival.
Dose reductions and toxicity
The prevalence and predictors of chemotherapy-related
complications are shown in Table 3. A PI-containing
cART was associated with a higher rate (as compared
with other antiretrovirals) of grade 3/4 haematological
toxicity in all histotypes. In those receiving antiretrovirals
(n = 323), the prevalence of chemotherapy-associated
complications, stratified according to main lymphoma
histotypes, is depicted in Figure 2.
Discussion
In this large retrospective analysis, we have described the
determinants of survival in HIV-positive patients present-
ing with HL and NHL: a diagnosis performed in recent
years, better immunovirological status, lower lymphoma
stage, better prognostic indexes and the choice of a non-
interacting cART were associated with better survival.
Although heterogeneous, this cohort included several
patients with various HIV-associated lymphomas present-
ing features usually associated with severe immune
depression such as extranodal and bone marrow involve-
ment, advanced stage and low prognostic indexes [22].
Approximately 70% of all patients presented comorbidi-
ties further complicating the management of the haema-
tological malignancies. HLs were observed in patients
who had higher CD4 cell counts and who were more
often on ART, as generally reported [23].
Survival was similar to that previously reported in the
literature, with approximately 50% long-term OS in
patients with NHL and 65–70% in patients with HL. Anti-
neoplastic treatments varied by centre and year of diag-
nosis: the management of HIV-positive subjects improved
over time, as demonstrated by the higher survival and
the higher use of rituximab in NHL and BL patients in
recent years. Conversely, a relatively low number of
patients with BL received an infusional intensive antineo-
plastic regimen (40%): nevertheless, the 5-year survival
was comparable to that of other cohorts, including HIV-
positive and HIV-negative subjects [24,25].
The selection of cART had an impact on the survival of
the included patients. While those who did not start any
treatment were possibly those with worse baseline status
for whom treatment was considered inappropriate, PI-
based regimens were often used in late-presenting
patients. The rationale supporting the use of PIs was the
need for high genetic barrier drugs and good immunolo-
gical recovery in patients presenting with very low CD4
counts. PI-associated DDIs and toxicities started to be
reported in 2005 and led to the further suggestion to
avoid antiretrovirals that may interact with vinca alka-
loids [26–29]. Higher vincristine and vinblastine concen-
trations have been associated with haematological and
neurological toxicities, potentially leading to chemother-
apy dose reductions or delays and therefore potentially
impairing antineoplastic efficacy. We did not observe a
significant effect on these outcomes but we did observe
an effect on the incidence of haematological toxicities; in
patients with HL, although the effect was nonsignificant,
chemotherapy dose reductions and infections were more
common in patients on PIs. Additionally, specific factors
have been associated with complications during antineo-
plastic treatment, and they include bone marrow involve-
ment, low CD4 count at baseline and rituximab use. HCV
infection was associated, independently of lymphoma
histotype, with peripheral neuropathy. Chronic HCV
Fig. 1 Survival according to highly active antiretroviral therapy (HAART) use in all patients (left), patients with non-Hodgkin lymphoma (mid-
dle) and patients with Hodgkin lymphoma (right). Survival of patients with no HAART started (black lines), those on protease inhibitor (PI)-
based HAART (grey lines) and those on HAART based on other antiretrovirals (ARVs) (light grey lines) is depicted using Kaplan–Meier curves
and compared using log-rank test (p < 0.001, p < 0.001, p = 0.211 for left, middle and right models respectively).
© 2018 British HIV Association HIV Medicine (2018)
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infection may cause peripheral neuropathy but it has not
been identified as a risk factor during chemotherapy:
higher antineoplastic drug concentrations or pre-existing
subclinical neuropathy can explain this finding and war-
rant caution in HIV/HCV-infected patients presenting
with lymphomas.
In the multivariate analysis for survival, different prog-
nostic factors emerged. In NHLs, older age, lower baseline
CD4 count and PI use were associated with the risk of death.
Prognostic indexes were not retained in the final model,
although they were previously validated in other cohorts;
the bias of PI administration to patients with a worse clini-
cal status or with late presentation of HIV infection may
have affected this finding. In HLs, only earlier year of diag-
nosis and bone marrow involvement were found to predict
mortality: the smaller sample size was probably insufficient
to include all factors in the analysis.
Some limitations of this study should be acknowledged,
including the large time-span, the heterogeneous manage-
ment of patients in different clinical sites, the nonstan-
dardized use of antineoplastic regimens, and the
incomplete information on causes of death. Additionally,
the relatively small sample size did not allow us to anal-
yse the determinants of death in less common histotypes.
Despite earlier findings of PI-associated toxicities dur-
ing chemotherapy, no study has reported an association
between the use of PIs and survival: our results
strengthen the recommendation to avoid such compounds
and support the use of noninteracting drugs such as inte-
grase inhibitors. The patients included in this study were
Table 3 Prevalence and predictors of chemotherapy-associated complications
All NHL HL
Chemotherapy dose reduction n (%) 55 (17.5) 28 (13.9) 18 (22)
Predictors in multivariate analysis None Female gender None
Bone marrow involvement
Rituximab use
Grade 3/4 haematological toxicity n (%) 149 (68.7) 102 (67.1) 37 (77.1)
Predictors in multivariate analysis Baseline AIDS Bone marrow involvement PI-containing cART
Carlson index > 1 Carlson index > 1
PI-containing cART PI-containing cART
Peripheral neuropathy n (%) 39 (18.5) 21 (13.8) 15 (33.3)
Predictors in multivariate analysis HCV infection HCV infection HCV infection
Infection n (%) 134 (62.3) 100 (64.5) 23 (53.5)
Predictors in multivariate analysis Baseline CD4 Baseline CD4 None
Rituximab use
Opportunistic infection n (%) 70 (32.7) 49 (31.8) 15 (34.9)
Predictors in multivariate analysis None High risk (IPI) None
Rituximab use
cART, combination antiretroviral therapy; HCV, hepatitis C virus; NHL, non-Hodgkin lymphoma; HL, Hodgkin lymphoma; PI, protease inhibitor.
Fig. 2 Prevalence of chemotherapy-associated complications according to main lymphoma histotypes and antiretrovirals [protease inhibitors
(PIs) vs. non-protease inhibitors] in highly active antiretroviral therapy (HAART) recipients. Significant univariate associations (v2 or Fisher’s
exact test) are shown above the bars. NHL, non-Hodgkin lymphoma; HL, Hodgkin lymphoma.
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on raltegravir but, given the similar pharmacokinetic
pathways, the observed results may reasonably be
extended to dolutegravir-containing regimens.
In conclusion, our study demonstrates that, even in
recent years, HIV-associated lymphomas have been com-
mon in HIV-positive patients and that the choice of a
DDI-sparing cART regimen is paramount to enhance sur-
vival in this fragile population.
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